Biotherapeutics

#Biotherapeutics #Cancer research #Drug delivery #Drug discovery #Oncology

New oncology research and development collaboration

Genmab and Bolt Biotherapeutics have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for… Read More

#News

#Biologics / Biotechnology #Biotherapeutics

Bio-Techne further enhances its manufacturing capabilities

Bio-Techne has partnered with Autolomous to implement an electronic batch record system, AutoloMATE, at Bio-Techne’s GMP cellular manufacturing centre. Through this partnership, Bio-Techne will be able to offer electronic records to therapeutic companies utilising its non-viral gene delivery system, TcBuster, or contract cellular manufacturing services alongside working with Autolomous to… Read More

#News

#Biotechnology #Biotherapeutics #Drug delivery

Collaboration to develop new therapeutic drug conjugates

Aptamer and PinotBio have entered into a strategic collaboration agreement to develop Optimer-drug conjugates for targeted drug delivery, combining Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker. Optimer therapeutics are optimised aptamer solutions. Optimer-drug conjugates offer uniquely specific targeting vehicles for the delivery of… Read More

#News

#Antibodies #Biotherapeutics #Drug discovery #Drug targets #Genovac

Berkeley Lights: Improving antibody discovery

John Proctor, Senior Vice President of Antibody Therapeutics at Berkeley Lights, and Brian Walters, President/CEO of Genovac Antibody Discovery, talk with DDW’s Megan Thomas about the company’s new Beacon system, which the CRO believes may be the new gold standard in antibody discovery with the potential to up antibody discovery. Read More

#Editor's Choice #Exclusive Content #News

#Biotherapeutics #Drug development #Nanomedicine / nanotechnology #Research

New platform uses nanothechnolgy to deliver therapeutics

The Infection Innovation Consortium (iiCON) has launched The Nanotherapeutics Hub, based at the University of Liverpool in the UK, part of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT). The agreement will see The Nanotherapeutics Hub work with iiCON to support companies looking to develop nanotherapeutics to combat infectious diseases… Read More

#Editor's Choice #News

#Biotherapeutics #Cell therapy #FDA #Tumour biology

What FDA Clearance means for GammaDelta cell cancer therapy

GammaDelta Therapeutics’ Investigational New Drug (IND) application has been cleared by the US Food and Drug Administration (FDA) for its allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for haematological malignancies. The FDA also granted orphan drug designation to allogeneic Vδ1… Read More

#News

#Biotherapeutics #Cardiovascular disease #Clinical trials #mRNA #Therapeutics

Positive data from study of siRNA in iron-loading anaemia conditions

Silence Therapeutics and Nasdaq have announced positive topline data from the GEMINI Phase I study of its wholly owned product candidate, SLN124, in healthy volunteers. SLN124, an siRNA which targets TMPRSS6, is in development for the treatment of iron-loading anaemia conditions, thalassemia and myelodysplastic syndrome (MDS). The GEMINI Phase I,… Read More

#News

#Biotherapeutics #Cell and gene therapy #Pharmaceutical #Therapeutics

Sector trio enters R&D alliance to develop cell therapies for eye diseases

BlueRock Therapeutics, FUJIFILM Cellular Dynamics and Opsis Therapeutics have entered a strategic research joint venture focused on developing cell therapies for patients with ocular diseases. The companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases. Under this agreement, BlueRock Therapeutics will have… Read More

#News

#Biotherapeutics #Drug candidates #Drug development #Therapeutics

Eli Lilly and MiNA Therapeutics saRNA research collaboration

Eli Lilly and Company and MiNA Therapeutics have created a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. MiNA will utilise its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly’s key… Read More

#News

#AstraZeneca #Biotherapeutics #Drug discovery #Immuno-oncology

Biotech collaboration to accelerate prostate cancer research

Alchemab has collaborated with AstraZeneca to work on a proof-of-concept study to build understanding of the fundamental biology of prostate cancer. Under the agreement, Alchemab’s novel drug discovery platform will be used as a diagnostic tool through the identification of disease biomarkers with potential to inform the development of novel… Read More

#News

#Biotherapeutics #Cancer research #Drug development #Immuno-oncology #Pharmaceutical

Janssen seeks approval for refractory multiple myeloma drug

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. Read More

#Cancer Research #News

#Biotherapeutics #Drug delivery #Drug development #Drug discovery #Research #Therapeutics

Making a difference in allergy and immune disorder treatments

Allergy Therapeutics is a pioneering immunology company, specialised in the research and development of allergy and immune disorder treatments that target the cause, rather than just manage the symptoms. Alan Bullimore, Head of Business Innovation spoke to Lu Rahman about the company’s work and the challenges and opportunities of this… Read More

#Exclusive Content #News #Opinion

#Biotechnology #Biotherapeutics #CRISPR #Drug discovery #Drug screening #Immunotherapy #Therapeutics

Platform biotechnologies and the art of collaboration

Despite its competitive nature, the drug discovery sector has embraced collaboration successfully, says Benedict Cross, Chief Technology Officer at Phoremost. The drug discovery and biotechnology industry is historically a competitive arena, both intellectually and commercially, where the race to the finish line can be characterised by unseemly acts of avaricious… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Biotherapeutics #Cancer research #DNA #Genetics #Radiology #Research

Researchers identify new role for protein in treatment of cancer

In a study by Yale Cancer Centre, researchers report on the discovery of a new role for STimulator of INterferon Genes, or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumour DNA damage… Read More

#Cancer Research #News

#Biologics / Biotechnology #Biotechnology #Biotherapeutics #Dementia

Dementia Discovery Fund enhances its neuroscience R&D expertise

The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, has announced the appointments of Dr Lynne Hughes and Dr James Summers as Venture Partners, bringing additional expertise in neuroscience research and development. Dr Jonathan Behr, Partner at The… Read More

#News

#Alzheimer's #Biotechnology #Biotherapeutics #Clinical trials #Drug development #Therapeutics

Clinical Ink adds 16th concurrent Alzheimer’s study

Clinical Ink, a clinical trial technology company, has announced the addition of its 16th concurrent Phase II/III Alzheimer’s disease study, exemplifying its ongoing commitment to this therapeutic area. Clinical Ink’s platform supports the needs of sponsors working on Alzheimer’s trials by using direct collection tools that allow for flexible data… Read More

#News